21514 Methylphenidate Clinical MTL PREA

First Page		Document Content
Attention-deficit hyperactivity disorder Clinical research Nootropics Stimulants Methylphenidate Daytrana Transdermal patch Attention deficit hyperactivity disorder Placebo Medicine Pharmacology Health		21514 Methylphenidate Clinical MTL PREA Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 35,89 KB Share Document on Facebook

	NOVEN PROVIDES UPDATE ON DAYTRANA® METHYLPHENIDATE TRANSDERMAL SYSTEM Shire Undertakes Non-Safety-Related Voluntary Market Withdrawal/Recall of a Limited Portion of Daytrana® Product Financial Reserve Established by No DocID: 1upp0 - View Document
	NOVEN TO ACQUIRE DAYTRANA® METHYLPHENIDATE TRANSDERMAL SYSTEM FROM SHIRE The First and Only Patch for ADHD to be Marketed and Sold by Noven Therapeutics Miami, FL, August 10, Noven Pharmaceuticals, Inc. today an DocID: 1ugJY - View Document
	FROM THE AMERICAN ACADEMY OF PEDIATRICS Guidance for the Clinician in Rendering Pediatric Care CLINICAL PRACTICE GUIDELINE DocID: 1ru0n - View Document
	Medical Information Form COMMUNITY GAMES MEDICAL INFORMATION FORM for PARTICIPANTS and U18 VOLUNTEERS All information given is strictly confidential This form must be completed in addition to the Community Games Registr DocID: 1rs9G - View Document
	Patrick Henry Academy Permission for School Administration of Medication Medications should be administered by a parent or guardian before or after school hours, when possible. Initial dosages of medication that a child DocID: 1ro6f - View Document